Press Releases
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
2, March, 2024
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
19, February, 2024
See all
News
Interview with CEO Carlos de Sousa in Finansavisen TV
14, February, 2024
Biostock Article: About the NIPU study and interview with the Director of Medical Affairs at Ultimovacs, Espen Basmo Ellingsen
6, June, 2023
Ultimovacs Presentation at TD Cowen Healthcare Conference
6, March, 2023
Article published in Current Opinion in Oncology: “Therapeutic cancer vaccination against telomerase”
8, February, 2023
See all